Current Medical Research and Opinion最新文献

{"title":"Frontiers in bibliometric analysis: the overrepresentation of bibliometric analyses in Grey publisher journals.","authors":"Joshua Wang","doi":"10.1080/03007995.2025.2488949","DOIUrl":"10.1080/03007995.2025.2488949","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"667-668"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of OFF period characteristics with patient communication behaviors in Parkinson's disease.","authors":"Radhika Devraj, Connie Marras, Marlon R Tracey","doi":"10.1080/03007995.2025.2495171","DOIUrl":"10.1080/03007995.2025.2495171","url":null,"abstract":"<p><strong>Objective: </strong>Underreporting of OFF symptoms and poor patient-provider communication are known challenges in Parkinson's disease (PD). We aimed to determine: (a) OFF period patient communication behavior components and (b) whether OFF period characteristics (frequency, duration, severity) were associated with communication behaviors.</p><p><strong>Methods: </strong>A retrospective cohort study using the Fox Insight database was conducted. OFF periods were characterized by frequency (number of episodes/day), duration (duration/episode), and severity (impact on activities). The \"Impact and Communication about OFF periods\" questionnaire data were subjected to principal components analysis. Generalized linear model regressions with log link function were used to identify associations with OFF period characteristics.</p><p><strong>Results: </strong>Data from 526 respondents showed that 89% were non-Hispanic whites, mean age = 65 ± 8.9 years, with PD duration = 6 ± 4.8 years. The majority (67%) had a frequency of 1-2 OFF periods/day, with the highest percent (31.4%) having 15-30 min OFF periods duration, and majority (63%) having none-to-some OFF periods severity. Two component communication behaviors were identified: (1) reluctance communicating (7 items, Cronbach's alpha (CA) = 0.851) and difficulty communicating (4 items, CA = 0.857). Above-average OFF periods severity was associated with a 12% higher reluctance score (beta = 0.117, 95% confidence interval (CI) = 0.03-0.21, <i>p</i> = 0.024). Higher OFF periods frequency and above-average severity were associated with greater difficulty communicating (Frequency: beta = 0.125, 95% CI = 0.03-0.22, <i>p</i> = 0.024; Severity: (beta = 0.186, 95% CI = 0.08-0.29, <i>p</i> = 0.003)) about OFF periods.</p><p><strong>Conclusion: </strong>Patient communication about OFF periods involves two main factors: their difficulty and reluctance to communicate. Greater frequency and severity of OFF periods were associated with greater difficulty and reluctance to communicate. Understanding these relationships can guide providers to take preemptive efforts to promote OFF periods communication, enhancing care quality.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"647-656"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.","authors":"Ekkehard Beck, Mihaela Georgieva, Wei-Jhih Wang, Andres Gomez-Lievano, Hongjue Wang, Yipeng Gao, Hagit Kopel, Mary Bausch-Jurken, Oscar Patterson-Lomba, Fan Mu, Eric Wu, Nicolas Van de Velde","doi":"10.1080/03007995.2025.2466726","DOIUrl":"10.1080/03007995.2025.2466726","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 continues to pose a significant health burden, particularly among older adults. mRNA-1283 is a next-generation COVID-19 mRNA vaccine developed to enhance immune response. Findings from the Phase 3 NextCOVE trial comparing bivalent versions of mRNA-1273 and mRNA-1283 vaccines have recently become available. However, there are no head-to-head trials comparing mRNA-1283 and the BNT162b2 vaccine.</p><p><strong>Objective: </strong>To indirectly compare the effectiveness of mRNA-1283 and BNT162b2 against symptomatic COVID-19 among adults in the US.</p><p><strong>Methods: </strong>A targeted literature review was conducted to identify relevant studies comparing the mRNA-1273 and BNT162b2 bivalent vaccines. A real-world evidence (RWE) study by Kopel et al. (2023) assessing the relative vaccine effectiveness (rVE) of mRNA-1273 vs. BNT162b2 was selected for an indirect treatment comparison (ITC) against the NextCOVE trial using the Bucher method. Analyses were stratified by age group and sensitivity analyses were conducted using alternative outcome definitions.</p><p><strong>Results: </strong>Despite differences between NextCOVE and the Kopel study, comparability assessments supported a robust ITC. Among participants ≥18 years of age, the indirect rVE of mRNA-1283 vs. BNT162b2 against symptomatic COVID-19 was 15.3% (95% CI = 4.7-24.8%, <i>p</i> = 0.006). For adults ≥65 years of age, the rVE was 22.8% (95% CI = 3.7-38.1%, <i>p</i> = 0.022). Sensitivity analyses with alternative outcome definitions supported these estimates.</p><p><strong>Conclusion: </strong>This analysis provides consistent and statistically significant evidence indicating the next-generation mRNA-1283 vaccine is more effective in preventing symptomatic COVID-19 than BNT162b2, with the largest effect in individuals aged ≥65. Consistent results across sensitivity analyses underscore the robustness of the findings, offering important evidence to inform vaccination decisions by policymakers, providers, and payers.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"721-732"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incremental healthcare costs among patients experiencing adverse events on oral antipsychotics: a real-world analysis of U.S. Medicare beneficiaries with schizophrenia.","authors":"Christopher Zacker, Justin T Puckett, Sachin Kamal-Bahl","doi":"10.1080/03007995.2025.2493344","DOIUrl":"10.1080/03007995.2025.2493344","url":null,"abstract":"<p><strong>Objective: </strong>Continuous antipsychotic treatment is fundamental to successful management of schizophrenia. However, many oral antipsychotics are associated with adverse effects (AEs). While prior research has shown antipsychotic AEs to negatively impact patient adherence, no study has examined the incremental costs associated with AEs, especially among Medicare beneficiaries who constitute approximately half of all patients with schizophrenia in the U.S. This study aimed to compare incremental healthcare costs among Medicare beneficiaries with schizophrenia treated with oral antipsychotics who did and did not experience adverse events (AEs).</p><p><strong>Methods: </strong>All fee-for-service Medicare beneficiaries with schizophrenia who initiated a new OAP between 01/01/2017 and 12/31/2019 were included in the sample (index date = date of new OAP prescription). All-cause and schizophrenia-related costs were measured while a patient was receiving treatment and were converted into monthly measures given differential follow-up periods. Generalized linear models were used to generate adjusted cost estimates.</p><p><strong>Results: </strong>In our final sample of 46,452 Medicare beneficiaries with schizophrenia, movement disorders such as tardive dyskinesia and extrapyramidal symptoms were observed in 10.0% of beneficiaries. Metabolic side effects included hyperlipidemia (33.6%), diabetes (33.1%), and hypotension (6.8%). Patients who experienced adverse events consistently had significantly higher all-cause monthly healthcare costs compared to patients who did not experience adverse events. This was true for beneficiaries experiencing movement disorders ($5,281 vs. $4,851, Δ = $430, <i>p</i> = 0.0766), hyperlipidemia ($5,123 vs. $4,768, Δ = $355, <i>p</i> = 0.0179), diabetes ($5,249 vs. $4,698, Δ = $551, <i>p</i> = 0.0049), and hypotension ($6,631 vs. $4,685, Δ = $1,946, <i>p</i> < 0.001). A similar pattern was observed for monthly schizophrenia-related costs.</p><p><strong>Conclusions: </strong>Our findings underscore the additional healthcare cost burden associated with adverse events in patients receiving oral antipsychotic treatment. Efforts should be directed towards selecting agents that minimize side effects and/or developing new therapeutic alternatives with improved tolerability profiles.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"587-592"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Frontiers in bibliometric analysis: the overrepresentation of bibliometric analyses in grey publisher journals\".","authors":"Jimmy Li, Charles Deacon, Mark Robert Keezer","doi":"10.1080/03007995.2025.2488948","DOIUrl":"10.1080/03007995.2025.2488948","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"669-670"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of administrative claims and clinical data to advance real-world evidence generation in oncology.","authors":"Chi Nguyen, Hanke Zheng, Michael Grabner, John Barron, Ruth Wangia Dixon, Mark Cziraky, Brian Sweet, Nathan Hill","doi":"10.1080/03007995.2025.2482665","DOIUrl":"10.1080/03007995.2025.2482665","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to evaluate capabilities of the Generating Evidence Excellence (GEx) research environment using Non-Small Cell Lung Cancer (NSCLC) as a use-case.</p><p><strong>Methods: </strong>Patients with incident NSCLC were identified in GEx from 01/01/2015 to 12/31/2019. Two GEx data containers were used: (1) claims from the Healthcare Integrated Research Database (HIRD) linked to clinical data from a Cancer Care Quality Program (CCQP) (HIRD+CCQP); (2) claims data from the HIRD and a second large commercially insured claims dataset (CD2) linked to electronic medical records from IntrinsiQ Specialty Solutions (IQSS) (HIRD+CD2 + IQSS). Patient demographics and all-cause mortality were contrasted with the American Community Survey and the United States Cancer Statistics (USCS) public use database. Descriptive analyses were completed <i>via</i> SAS Enterprise Guide 7.12 and SEER*stat.</p><p><strong>Results: </strong>The study sample comprised of 6,233 (HIRD+CCQP) and 1,176 (HIRD+ CD2 + IQSS) patients with NSCLC. Both GEx data containers had similar patient demographics with a mean age 63 years and 71% White, while 70% of USCS patients were ≥65 years and 85% White. Most patients resided in the South/Midwest regions of the US (74% (HIRD+CCQP) and 86% (HIRD+CD2 + IQSS). Patients in GEx over-represented the working-age group, i.e. 65% were between 18 and 65 years old. Stage IV disease was frequently recorded at diagnosis (59.4% HIRD+CCQP, 44.0% HIRD+CD2 + IQSS, 46.1% USCS). All-cause mortality rate was 38.8 (HIRD+CCQP) and 27.3 (HIRD+CD2 + IQSS) per 100 person-years.</p><p><strong>Conclusions: </strong>The analysis of NSCLC as a use-case demonstrated that GEx is a valuable data ecosystem with a generalizable working-age patient population and comprehensive data to facilitate timely real-world evidence generation in oncology.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"671-681"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aspiration risk and strategic approach for patients receiving GLP-1 receptor agonists undergoing elective surgery.","authors":"Juan Li, Basma Mohamed, Shun Huang, Yong G Peng","doi":"10.1080/03007995.2025.2494646","DOIUrl":"10.1080/03007995.2025.2494646","url":null,"abstract":"<p><p>Perioperative management of patients receiving a glucagon-like peptide-1 receptor agonist (GLP-1 RA) remains challenging for the anesthesiologist. Despite the approval of GLP-1 RAs 2 decades ago, the recent reports of aspiration and postoperative pulmonary complications drew attention to this group of medications and resulted in multiple societal guidelines that would provide recommendations for anesthesiologists and proceduralists on the appropriate perioperative management of GLP-1 RAs. However, despite these guidelines and proposed options, there was a lack of adequate evidence to support holding versus continuing the medication, as well as data related to the role of gastric ultrasound in that decision-making process. The release of multiple societal guidelines and studies evaluating the impact of GLP-1 RAs on perioperative outcomes resulted in more controversy and uncertainty for the clinician anesthesiologist to follow. The ultimate goal for perioperative management of these medications is to evaluate an individual patient's risk of aspiration, rather than assuming the risk is low when holding the medication appropriately or high if not holding it. Furthermore, it is unclear whether holding these types of medicines or unnecessary postponing of surgery may result in adverse outcomes. In this narrative review, we present a summary of the existing literature on the topic with a focus on the risk of aspiration and a recommendation for perioperative management to include the utilization of gastric ultrasound for surgery patients based on their risks.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"699-712"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare resource use and clinical events associated with neutropenia among adult kidney transplant recipients receiving valganciclovir or ganciclovir prophylaxis: a matched case-control cohort study.","authors":"Weijia Wang, Pamela A Moise, Michael Wong, Wei Gao, Cheryl Xiang, Abigail Zion, Flavio Vincenti, Andrew P Beyer","doi":"10.1080/03007995.2025.2498674","DOIUrl":"10.1080/03007995.2025.2498674","url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus prophylaxis with valganciclovir and ganciclovir is associated with increased neutropenia risk in kidney transplant recipients. This study assessed the association between neutropenia and short-term healthcare resource utilization (HCRU) and clinical events for adults receiving valganciclovir and/or ganciclovir prophylaxis post-kidney transplantation in the United States.</p><p><strong>Methods: </strong>Adult kidney transplant recipients from 2012 to 2020 who received valganciclovir and/or ganciclovir prophylaxis were identified in the TriNetX database. Patients with a neutropenia event during the 1-year post-kidney transplant were identified as cases and those without were identified as controls. Cases and controls were matched 1:1 on patient characteristics in the 1-year period before the kidney transplant. HCRU and clinical event rates in the year following the first neutropenia event were compared between the cases and controls.</p><p><strong>Results: </strong>Of 3564 identified case-control pairs, the average age was 52 years and 59.57% were male. Cases had higher HCRU in the first year after neutropenia than controls, characterized by 1.40-, 1.28-, and 1.33-times higher rates of inpatient, outpatient, and emergency department visits (all <i>p</i> < 0.001). Cases also had higher incident rates for cytomegalovirus-related events, use of granulocyte colony stimulating factor, and opportunistic infections (all adjusted incident rate ratios >1 with <i>p</i> < 0.01), and greater risks of death, graft loss, and acute graft rejection (all adjusted hazard ratios >1 with <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Higher HCRU and clinical burden were observed within the first year following post-transplant neutropenia. New options for cytomegalovirus prophylaxis that are less likely to induce neutropenia are needed to improve patient outcomes.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"639-646"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influenza burden among chronic condition and immunocompromised patients in the United States.","authors":"Prajakta Bhounsule, Keith Boundy, Susan Mehle, Matt Chang, Robert Sedgley, Joe Vasey","doi":"10.1080/03007995.2025.2492646","DOIUrl":"10.1080/03007995.2025.2492646","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective cohort study examined influenza-like illness (ILI) in the United States during the 2017-2018 season among vaccinated adults who are immunocompromised or have high-risk chronic conditions. Results among adults with no evidence of vaccination (NEoV) were included to help contextualize study findings.</p><p><strong>Methods: </strong>The Veradigm Network EHR linked to claims data were used to identify adults (≥18 years old) with continuous enrollment in claims between 1 October 2016 and 20 May 2018. Patients were stratified by evidence of influenza vaccination between 1 August 2017 and 6 May 2018 (vaccinated or no evidence of vaccination [NEoV]). Individuals were classified as immunocompromised or with a high-risk chronic condition based on diagnoses and treatments between 1 October 2016 through 1 October 2017. The main outcome of interest was influenza-like illness (ILI) during the influenza season.</p><p><strong>Results: </strong>A total of 2,763,671 vaccinated individuals and 7,702,021 individuals with NEoV were identified, of whom 2.5% and 1.2%, respectively, were in the immunocompromised subgroup, while 6.7% and 3.2% had at least one high-risk chronic condition. The percentages of patients with an ILI were 2.5% and 2.7% in the overall vaccinated and NEoV cohorts, 3.1% and 3.5% in the immunocompromised subgroups, and 3.0% and 3.2 in the chronic conditions subgroups. Multivariable modeling of odds of ILI among vaccinated individuals found that chronic obstructive pulmonary disease, rheumatoid arthritis, and end stage renal disease were the diagnoses most strongly associated with increased odds of ILI.</p><p><strong>Conclusion: </strong>There remains an unmet need for additional prophylactic agents that reduce the incidence and severity of ILI among patients who are immunocompromised or have chronic conditions.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"607-615"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The real-world effectiveness of ustekinumab in patients with ulcerative colitis in the United States.","authors":"Sabree Burbage, Hannah Knight, Bridget Godwin, Rachael Meadows, William Jones, Ruizhi Zhao, Sumesh Kachroo","doi":"10.1080/03007995.2025.2494642","DOIUrl":"10.1080/03007995.2025.2494642","url":null,"abstract":"<p><strong>Background: </strong>Ustekinumab was approved for use in the treatment of moderate/severe ulcerative colitis (UC) in 2019. Though it has proven effective in clinical trials, evidence of its effectiveness in clinical practice is limited to the published reports of use in clinical practice. This study assessed ustekinumab effectiveness in patients with UC presenting in real-world clinical practice.</p><p><strong>Methods: </strong>Data were drawn from the Adelphi Real World Inflammatory Bowel Disease (IBD) Disease Specific Programme, a cross-sectional survey of physicians and their IBD patients in the USA from December 2022 to January 2024. Physicians provided demographics and clinical characteristics, treatment patterns, symptoms, and remission status for UC patients aged ≥18 years old who were prescribed ustekinumab for >1 day. Analyses were descriptive; McNemar's test was used to compare symptoms and disease severity before and after ustekinumab prescription.</p><p><strong>Results: </strong>Overall, 56 physicians reported on 185 patients. Mean (standard deviation) patient age was 39.7 (12.9) years and 53.0% were female. Most patients were advanced therapy-naïve at ustekinumab initiation (65.9%) and had taken ustekinumab for ≥3 months (84.6%). At survey, 53.0% were in remission defined by Mayo score, and 61.9% were in physician-stated clinical remission. Reports of abdominal pain, bowel urgency, nighttime urgency, and bloody diarrhea were more than halved at survey compared to pre-ustekinumab, with reductions in fatigue and non-bloody diarrhea also seen (all <i>p</i> < 0.0001).</p><p><strong>Conclusion: </strong>Overall, ustekinumab is an effective treatment for UC in real-world clinical practice capable of inducing and maintaining long-term remission. Future work should assess how ustekinumab impacts quality of life.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"683-689"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}